The Scottish Medical Consortium have recommended Pembrolizumab (Keytruda) as a monotherapy which is indicated for the adjuvant treatment of adults with RCC with increased risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic...
Like everyone we have faced much adversity over the last 6 months. As a charity our team have shown incredible resilience to ensure longevity and the continuation of support that we provide to patients or those diagnosed with kidney cancer. We do not receive any...
Kidney Cancer Scotland add their voice to those praising the Scottish Medicine Consortium's (SMC) approval of the therapy Keytruda (pembrolizumab) in combination with Inlyta (axitinib) for kidney cancer patients in Scotland. Following positive trials results, the news...
We have a free telephone Counselling service and a freephone Careline, there to support patients across Scotland. Please feel free to call us, we are here for you.
0800 002 9002
Our work depends on donations from generous people so that we can support those affected by kidney cancer.
Would you like to support our work through a donation?
